Mark E. Dunlap, MD

Shyam Bhakta, MD
Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland

Mark E. Dunlap, MD
Director, Heart Failure Program and Associate Chief, Cardiology Section, Louis B. Stokes Veterans Affairs Medical Center; Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University, Cleveland; national leader, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial

Address: Mark E. Dunlap, MD, Cardiology Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106

Dr. Dunlap has indicated that he has received grant or research support from, is a consult for, and is on the speakers’ bureau of the AstraZeneca corporation, the maker of candesartan.

This paper discusses therapy that is experimental or not approved by the US Food and Drug Administration for the use under discussion.

Shyam Bhakta, MD
Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland

Mark E. Dunlap, MD
Director, Heart Failure Program and Associate Chief, Cardiology Section, Louis B. Stokes Veterans Affairs Medical Center; Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University, Cleveland; national leader, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial

Address: Mark E. Dunlap, MD, Cardiology Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106

Dr. Dunlap has indicated that he has received grant or research support from, is a consult for, and is on the speakers’ bureau of the AstraZeneca corporation, the maker of candesartan.

This paper discusses therapy that is experimental or not approved by the US Food and Drug Administration for the use under discussion.

Shyam Bhakta, MD
Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland

Mark E. Dunlap, MD
Director, Heart Failure Program and Associate Chief, Cardiology Section, Louis B. Stokes Veterans Affairs Medical Center; Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University, Cleveland; national leader, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial

Address: Mark E. Dunlap, MD, Cardiology Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106

Dr. Dunlap has indicated that he has received grant or research support from, is a consult for, and is on the speakers’ bureau of the AstraZeneca corporation, the maker of candesartan.

This paper discusses therapy that is experimental or not approved by the US Food and Drug Administration for the use under discussion.